Decibel Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021
Assets
Current assets:
Cash and cash equivalents
Available-for-sale securities
Accounts receivable from related party
Prepaid expenses and other current assets
Total current assets
Available-for-sale securities, long-term
Property and equipment, net
Right-of-use asset, operating
Right-of-use asset, finance
Other assets
Total assets
Liabilities and Stockholders Equity
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Deferred collaboration liability, current
Deferred rent and lease incentive obligation, current
Operating lease liability, current
Finance lease liability, current
Total current liabilities
Long-term liabilities:
Deferred collaboration liability, long term
Deferred rent and lease incentive obligation, long term
Operating lease liability, long-term
Finance lease liability, long-term
Other long-term liabilities
Total liabilities
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 25,126,935 shares issued and outstanding at June 30, 2023; 200,000,000 shares authorized, 24,964,502 shares issued and outstanding at December 31, 2022
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments